BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Medical College of Wisconsin and Cellular Dynamics International Awarded National Heart, Lung, and Blood Institute Grant Using Human Induced Pluripotent Stem Cells


7/6/2011 6:42:37 AM

MADISON, Wis., July 5, 2011 /PRNewswire/ -- The Medical College of Wisconsin (MCW) and Cellular Dynamics International (CDI) today announced receipt of a research grant award from the National Heart, Lung, and Blood Institute (NHLBI) to investigate the mechanisms underlying Left Ventricular Hypertrophy. Commonly known as an increase of the size and weight of the heart, Left Ventricular Hypertrophy is a common and major risk factor for heart disease and heart failure due to high blood pressure or diabetes. The MCW and CDI will use the grant funds, totalling $6.255,632 million over five years, to generate 250 induced pluripotent stem cell (iPSC) lines from blood samples drawn from Caucasian and African-American families in the Hypertension Genetic Epidemiology Network (HyperGEN). All of these families have an elevated burden of high blood pressure and are at significant risk for cardiovascular disease. The iPSC lines will then be differentiated into ventricular heart cells for use in experiments to better understand the genetic mechanisms underlying this disease.

iPSCs are created from adult cells, such as blood or skin, which are reverse engineered to a stem cell state, from which point they can turn into any cell type in the body. iPSCs can be made from any individual and avoid the political and ethical issues surrounding embryonic stem cells.

An increase of the weight of the heart is a common precursor of serious disorders including myocardial infarction and congestive heart failure. This grant will enable researchers to improve future methods for diagnosis, treatment, and prevention of these conditions.

HyperGEN involves scientists from six universities and the NHLBI who seek to identify the genetic contributions to hypertension. HyperGEN is unique because it is family-based, includes both Caucasians and African-Americans and is one of the largest genome-wide association studies (GWAS) with extensive clinical data available.

"This grant builds on years of our research to identify genes for this disease. We now have the wonderful opportunity to capitalize on the latest stem cell technology to study human heart cells in the laboratory," said Ulrich Broeckel, MD, Professor of Pediatrics, Medicine and Physiology at MCW and Associate Director at the Children's Research Institute. "This technology is truly revolutionary since each cell line stands for an individual patient, and we can now start to study the unique disease mechanisms and test new treatments and drugs based on each individual's unique genetic makeup. This grant also shows the strength of collaborations between academic investigators and a company which leads to cutting edge research."

"Funding of this grant will enable Cellular Dynamics to generate an unprecedented 250 human iPSC lines as well as heart cells derived from those lines," said Emile Nuwaysir, Chief Operating Officer of CDI. "Until now, functional studies for left ventricular hypertrophy have been limited because human primary cardiomyocytes, or heart cells taken from living tissue, were not available for functional analysis. Human iPSC technology provides a solution to this problem. CDI's human iPSC-derived heart cells, iCell® Cardiomyocytes, exhibit properties highly similar to human primary cells and thus are a relevant model system for the required functional analysis. In addition, CDI is the only company with the capability to manufacture iPSCs and differentiate them in large numbers and at high quality and purity from a typical, standard blood draw, thus enabling MCW to perform this series of experiments. We are particularly excited about this project because we see it as a harbinger of the next big scientific wave: the linking of genotype to phenotype through iPSC-derived terminal tissue cells."

About Medical College of Wisconsin

The Medical College of Wisconsin is the state's only private medical school and health sciences graduate school. Founded in 1893, it is dedicated to leadership and excellence in education, patient care, research and service. Approximately 1,200 students are enrolled in the Medical College's medical school and graduate school programs. A major national research center, it is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In FY 2009 -10, faculty received approximately $161 million in external support for research, teaching, training and related purposes, of which $148 million is for research. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, College faculty direct or collaborate on more than 2,000 research studies, including clinical trials. Additionally, more than 1,250 physicians provide care in virtually every specialty of medicine for more than 400,000 patients annually.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.

About Children's Research Institute

Children's Research Institute advances state-of-the-art pediatric health care practice through dedicated laboratory and clinical research. Based on the concept of translational research, the institute is designed to take clinical problems from patients' bedsides to study in the laboratory. Laboratory discoveries are then converted into new treatments, preventions, therapies and cures for patients. Children's Research Institute is affiliated with Children's Hospital of Wisconsin and is a member of Children's Hospital and Health System. The health system is able to fulfill its mission thanks in part to philanthropic gifts and support from members of the community. For more information visit the website at www.chw.org/research.

SOURCE Cellular Dynamics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->